Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outpatient ICE plus pegfilgrastim for stem cell mobilization in relapsed or refractory lymphoma
ACTRN12606000350527Phase 2Recruiting
- Sponsor
- Amgen
- Start
- Jul 2005
- Modality
- Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ifosfamide, carboplatin, etoposide and pegfilgrastim in diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), sponsored by Amgen. Primary endpoint: Ability of outpatient ICE plus pegfilgrastim to mobilize sufficient peripheral blood CD34+ stem cells. Started Jul 2005; status: recruiting.
02
Drugs
ifosfamidecarboplatinetoposidepegfilgrastim
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on ACTRN12606000350527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000350527.